Understand the source comparison
LL-37 Lyme Support: Research vs Clinical Timeline Comparison
Journal of Innate Immunity 2022 (synovial fluid analysis) 12 weeks Synovial LL-37 concentration vs bacterial load LL-37 levels inversely correlated with Borrelia DNA at 8–12 weeks Higher endogenous LL-37 = lower persistent infection Utrecht University 2021 (ch
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Journal of Innate Immunity 2022 (synovial fluid analysis)
- 12 weeks
- Synovial LL-37 concentration vs bacterial load
- LL-37 levels inversely correlated with Borrelia DNA at 8–12 weeks
- Higher endogenous LL-37 = lower persistent infection
- Utrecht University 2021 (chronic Lyme arthritis cohort)
- 16 weeks
- Inflammatory cytokine profile (IL-6, TNF-alpha)
- Cytokine normalisation at 10–14 weeks in responders
- Symptom relief lags biomarker improvement by 2–4 weeks
- Observational peptide therapy data (Real Peptides client base)
- 6 months
- Patient-reported symptom scores (fatigue, pain, cognition)
- Meaningful improvement (>30% reduction) at 8–16 weeks
- Wide individual variation. Co-infections delay response
- In vitro Borrelia studies (multiple institutions)
- N/A (laboratory model)
- MIC (minimum inhibitory concentration)
- Spirochete membrane disruption at 8–16 μg/mL
- Achievable plasma levels require vitamin D optimisation
- Professional Assessment
- .
- LL-37 works as immune reconstitution support, not standalone antibiotic replacement. Expect 8–12 weeks minimum for biomarker shifts; symptom relief follows, not precedes, those shifts. Herxheimer reactions weeks 2–6 are normal and indicate immune activation.